Phase III success in two studies for cariprazine (Forest/Richter) in Schizophrenia

Positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188), from Forest Labs and Gedeon Richter, were announced for the treatment of acute exacerbation of schizophrenia. For the primary endpoint in each study, the Positive And Negative Syndrome Scale (PANSS), the data showed that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients. All doses showed statistically significant separation from placebo starting at week 2 and at each subsequent time point with the higher dose showing separation as early as week 1 of treatment. Further analyses of the data in each study will be completed in the coming weeks. The results of these 2 studies were consistent with the results of the previously completed placebo-controlled Phase IIb fixed-dose study in this population.